학술논문
Differences in glucose metabolic activity in liver metastasis separates two groups of metastatic uveal melanoma patients with different prognosis.
Document Type
Academic Journal
Author
Del Carpio LP; Medical Oncology Department, Institut Català d'Oncologia - ICO, L'Hospitalet de Llobregat, IDIBELL, Barcelona, Spain.; Cancer ImmunoTherapy (CIT) Group - iPROCURE, Bellvitge Biomedical Research Institute IDIBELL-OncoBell, L'Hospitalet de Llobregat, Barcelona, Spain.; Algarra MA; Medical Oncology Department, Instituto Valenciano de Oncología - IVO, Valencia, Spain.; Sabaté-Llobera A; Nuclear Medicine Department, Institut de Diagnòstic per la Imatge - IDI, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.; Rodriguez-Vida A; Medical Oncology Department, Hospital del Mar, Barcelona, Spain.; Rossi-Seoane S; Nuclear Medicine Department, Institut de Diagnòstic per la Imatge - IDI, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.; Nuclear Medicine Department, Centro Uruguayo de Imagen Molecular - CUDIM, Montevideo, Uruguay.; Ruiz S; Radiology Department, Hospital de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.; Leiva D; Radiology Department, Hospital de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.; Ramos E; Hepatic Surgery Department, Hospital de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.; Lladò L; Hepatic Surgery Department, Hospital de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.; Lorenzo D; Ophthalmology Department, Hospital de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.; Gutierrez C; Radiation Oncology Department, Institut Català d'Oncologia - ICO, L'Hospitalet de Llobregat, Barcelona, Spain.; Cortes-Romera M; Nuclear Medicine Department, Institut de Diagnòstic per la Imatge - IDI, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.; Caminal JM; Ophthalmology Department, Hospital de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.; Piulats JM; Medical Oncology Department, Institut Català d'Oncologia - ICO, L'Hospitalet de Llobregat, IDIBELL, Barcelona, Spain.; Cancer ImmunoTherapy (CIT) Group - iPROCURE, Bellvitge Biomedical Research Institute IDIBELL-OncoBell, L'Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer - CIBERONC, Madrid, Spain.
Source
Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE
Subject
Language
English
Abstract
Background: Uveal melanoma metastasizes to the liver. We aimed to explore the metabolic activity of liver metastases (LM) as a biomarker for survival.
Methods: We analyzed newly diagnosed patients with metastatic UM (MUM) with LM detected by liver-directed imaging and had undergone a PET/CT at diagnosis.
Findings: 51 patients were identified between 2004 and 2019. Median age was 62 years, 41% male and 22% ECOG ≥1. LDH, ALP, and GGT were elevated in 49%, 37%, and 57% of patients. Median LM SUVmax was 8.5 (3-42.2). Same size lesions presented a wide range of metabolic activity. Median OS was 17.3 m (95% CI:10.6-23.9). Patients with SUVmax ≥8.5 had an OS of 9.4 m (95% CI:6.4-12.3), whereas patients with SUVmax <8.5 had an OS of 38.4 m (95% CI:21.4-55.5; p < 0.0001, HR = 2.9). We observed similar results when studying M1a disease separately. Multivariate analysis showed SUVmax as an independent prognostic factor for the whole population and those with M1a disease.
Interpretation: Increased metabolic activity of LM seems to be an independent predictor of survival. MUM is a heterogeneous disease and metabolic activity probably reflects a different intrinsic behavior.
(© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
Methods: We analyzed newly diagnosed patients with metastatic UM (MUM) with LM detected by liver-directed imaging and had undergone a PET/CT at diagnosis.
Findings: 51 patients were identified between 2004 and 2019. Median age was 62 years, 41% male and 22% ECOG ≥1. LDH, ALP, and GGT were elevated in 49%, 37%, and 57% of patients. Median LM SUVmax was 8.5 (3-42.2). Same size lesions presented a wide range of metabolic activity. Median OS was 17.3 m (95% CI:10.6-23.9). Patients with SUVmax ≥8.5 had an OS of 9.4 m (95% CI:6.4-12.3), whereas patients with SUVmax <8.5 had an OS of 38.4 m (95% CI:21.4-55.5; p < 0.0001, HR = 2.9). We observed similar results when studying M1a disease separately. Multivariate analysis showed SUVmax as an independent prognostic factor for the whole population and those with M1a disease.
Interpretation: Increased metabolic activity of LM seems to be an independent predictor of survival. MUM is a heterogeneous disease and metabolic activity probably reflects a different intrinsic behavior.
(© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)